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1. INTRODUCTION {#rth212076-sec-0006}
===============

Atrial fibrillation (AF) is increasingly common as our population ages, with estimates indicating that the number of affected patients will reach 5.6 million by the year 2050.[1](#rth212076-bib-0001){ref-type="ref"} Atrial fibrillation has become a cardiovascular epidemic, and is associated with significant morbidity and mortality, with considerable implications for population disease burden and medical costs.[2](#rth212076-bib-0002){ref-type="ref"}, [3](#rth212076-bib-0003){ref-type="ref"}, [4](#rth212076-bib-0004){ref-type="ref"} Oral anticoagulants, which include vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs), are used to prevent thromboembolism including stroke and systemic embolism in this patient population.[5](#rth212076-bib-0005){ref-type="ref"}, [6](#rth212076-bib-0006){ref-type="ref"}, [7](#rth212076-bib-0007){ref-type="ref"}, [8](#rth212076-bib-0008){ref-type="ref"}, [9](#rth212076-bib-0009){ref-type="ref"}, [10](#rth212076-bib-0010){ref-type="ref"}, [11](#rth212076-bib-0011){ref-type="ref"}, [12](#rth212076-bib-0012){ref-type="ref"} Patients on oral anticoagulants frequently undergo invasive procedures that require temporary interruption of anticoagulation. The increasing prevalence of AF, as well as the need to interrupt anticoagulation for invasive procedures poses a growing problem for a wide variety of clinicians.[13](#rth212076-bib-0013){ref-type="ref"} Previous expert narrative reviews have provided guidance to clinicians on the management of DOACs in the perioperative period.[14](#rth212076-bib-0014){ref-type="ref"}, [15](#rth212076-bib-0015){ref-type="ref"} In order to update these expert reviews with clinical data, we conducted a systematic review and meta‐analysis of the literature on the perioperative management of DOACs in patients with AF. Our aim was to assess risk of perioperative thromboembolism and bleeding following the perioperative interruption of DOACs.

2. METHODS {#rth212076-sec-0007}
==========

2.1. Search strategy {#rth212076-sec-0008}
--------------------

We conducted a systematic literature search using EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials. The PICO question was: In patient with AF on DOACs for stroke prevention requiring perioperative temporary interruption of their anticoagulation regimen for a procedure, what is the 30‐day risk for thromboembolic and major bleeding events? The full search strategy is available in the supporting information. References of included studies, narrative reviews and recent conference proceedings of major international conferences were reviewed for additional studies. There were no restrictions with respect to date of publication or language. The systematic review protocol and search strategy were registered online (PROSPERO January 27, 2017: CRD42017056124).

2.2. Study selection {#rth212076-sec-0009}
--------------------

Two authors (JS and JW) independently identified studies eligible for inclusion based on an initial screen of reference titles and abstracts. Articles were included for further review if they evaluated the perioperative interruption of a DOAC (dabigatran, rivaroxaban, apixaban, or edoxaban) in patients with AF, and reported both postoperative thromboembolic and bleeding outcomes. Randomized controlled trials, prospective and retrospective studies were included. Studies that exclusively evaluated the perioperative interruption of DOACs for cardiac ablation were excluded, as well as those exclusively evaluating urgent/emergent procedures. Article records were independently reviewed for inclusion in duplicate, and discrepancies were resolved by consensus.

2.3. Data extraction and quality assessment {#rth212076-sec-0010}
-------------------------------------------

Two authors (JS and JW) independently extracted data using a standardized form. Primary outcomes of interest included 30‐day risk of perioperative thromboembolic and major bleeding. Secondary outcomes of interest included 30‐day risk of perioperative minor bleeding and all‐cause mortality. Outcomes were defined according to what was used in the included studies. Thromboembolic events were defined as stroke or systemic embolism. Major bleeding was defined according to the criteria of the International Society on Thrombosis and Haemostasis.[16](#rth212076-bib-0016){ref-type="ref"}, [17](#rth212076-bib-0017){ref-type="ref"}, [18](#rth212076-bib-0018){ref-type="ref"} Minor bleeding was defined as bleeding events not meeting the major bleeding criteria. The quality of randomized controlled trials was assessed using the Cochrane Collaboration\'s tool for assessing risk of bias. The quality of cohort/case‐control studies was assessed using the Newcastle‐Ottawa Scale.

2.4. Statistical analysis {#rth212076-sec-0011}
-------------------------

Outcomes were reported per perioperative interruption. Pooled percentages and 95% confidence intervals of primary and secondary outcomes were generated using Stat Direct 3.1.11 software (Cheshire, UK). Forest plots of randomized controlled data (DOACs vs. VKAs) were also generated using Revman 5.3 software (London, UK). Analyses were conducted using a random effects model (DerSimonian‐Laird analysis). Subgroup analysis of studies assessing interruption of dabigatran was conducted. The *I* ^2^ statistic was used to estimate total variation among the pooled estimates across studies. An *I* ^2^ of \<25% was considered as low‐level heterogeneity, 25% to 50% was moderate level and higher than 50% was considered as high level.[19](#rth212076-bib-0019){ref-type="ref"}

3. RESULTS {#rth212076-sec-0012}
==========

3.1. Study characteristics {#rth212076-sec-0013}
--------------------------

Our literature search identified an initial 917 records, of which 46 studies met our preliminary inclusion criteria based on title and abstract screening. A total of 8 publications including 14 446 patients and 17 107 periprocedural interruptions met full eligibility criteria (Table [1](#rth212076-tbl-0001){ref-type="table"}, Figure [1](#rth212076-fig-0001){ref-type="fig"}).[20](#rth212076-bib-0020){ref-type="ref"}, [21](#rth212076-bib-0021){ref-type="ref"}, [22](#rth212076-bib-0022){ref-type="ref"}, [23](#rth212076-bib-0023){ref-type="ref"}, [24](#rth212076-bib-0024){ref-type="ref"}, [25](#rth212076-bib-0025){ref-type="ref"}, [26](#rth212076-bib-0026){ref-type="ref"}, [27](#rth212076-bib-0027){ref-type="ref"} Four studies consisted of post‐hoc retrospective analyses of prospectively collected randomized controlled trial data and the remaining four studies were prospective or retrospective cohort studies. Five studies evaluated the perioperative interruption of dabigatran, whereas there was one study for each of rivaroxaban, apixaban and edoxaban.

###### 

Study characteristics

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References                                  Year   Author     Design                 DOAC/VKA          CHADS~2~ (mean ± SD) (median (IQR))   No. of Patients   No. of Interruptions
  ------------------------------------------- ------ ---------- ---------------------- ----------------- ------------------------------------- ----------------- ----------------------
  [20](#rth212076-bib-0020){ref-type="ref"}   2012   Healey     RCT                    Dabigatran 150\   2.1 ± 1.1\                            4591              4591
                                                                                       Dabigatran 110\   2.1 ± 1.1\                                              
                                                                                       Warfarin          2.1 ± 1.1                                               

  [21](#rth212076-bib-0021){ref-type="ref"}   2014   Sherwood   RCT                    Rivaroxaban\      3.40 ± 0.95\                          2130              2980
                                                                                       Warfarin          3.42 ± 0.96                                             

  [22](#rth212076-bib-0022){ref-type="ref"}   2014   Garcia     RCT                    Apixaban\         2.1 ± 1.1\                            3930              5741
                                                                                       Warfarin          2.1 ± 1.1                                               

  [23](#rth212076-bib-0023){ref-type="ref"}   2015   Douketis   RCT                    Edoxaban 60\      2.8 ± 0.9\                            3116              3116
                                                                                       Edoxaban 30\      2.9 ± 0.9\                                              
                                                                                       Warfarin          2.8 ± 1.0                                               

  [24](#rth212076-bib-0024){ref-type="ref"}   2015   Schulman   Prospective Cohort     Dabigatran/‐      --                                    531               531

  [25](#rth212076-bib-0025){ref-type="ref"}   2014   Kosiuk     Prospective Cohort     Dabigatran/‐      4 (3‐5)                               85                85

  [26](#rth212076-bib-0026){ref-type="ref"}   2014   Terekhov   Prospective Cohort     Dabigatran/‐      --                                    16                16

  [27](#rth212076-bib-0027){ref-type="ref"}   2016   Madan      Retrospective Cohort   Dabigatran/‐      --                                    47                47
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DOAC, Direct Oral Anticoagulant; RCT, Randomized Controlled Trial; VKA, Vitamin K Antagonist.

John Wiley & Sons, Ltd

![Study flow diagram](RTH2-2-282-g001){#rth212076-fig-0001}

3.2. Procedural characteristics {#rth212076-sec-0014}
-------------------------------

Three cohort studies exclusively included patients undergoing permanent pacemaker insertion or implantable cardioverter defibrillator procedures. Five studies included patients undergoing a variety of procedures (Table [2](#rth212076-tbl-0002){ref-type="table"} and Table [3](#rth212076-tbl-0003){ref-type="table"}). Of the eight included studies, five had defined perioperative anticoagulation protocols. Timing of anticoagulation discontinuation/resumption and the use of bridging anticoagulation were variable across studies (Table [2](#rth212076-tbl-0002){ref-type="table"}).

###### 

Procedural characteristics

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References                                  Author     Defined Perioperative Anticoagulation Protocol   DOAC/VKA          Emergent %/(n)   Bridging %/(n)   Procedural Type (%)
  ------------------------------------------- ---------- ------------------------------------------------ ----------------- ---------------- ---------------- ---------------------------------
  [20](#rth212076-bib-0020){ref-type="ref"}   Healey     Yes                                              Dabigatran 150\   9.1 (141)\       17.0 (263)\      PPM/ICD (10.3)\
                                                                                                          Dabigatran 110\   4.2 (63)\        15.3 (228)\      Dental (10.0)\
                                                                                                          Warfarin          7.1 (111)        28.5 (444)       Diagnostic (10.0)\
                                                                                                                                                              Cataract Removal (9.3)\
                                                                                                                                                              Colonoscopy (8.6)\
                                                                                                                                                              Arthroplasty (6.2)\
                                                                                                                                                              Other (45.6)

  [21](#rth212076-bib-0021){ref-type="ref"}   Sherwood   Yes                                              Rivaroxaban\      Unknown          Unknown          Colonoscopy (17.0)\
                                                                                                          Warfarin                                            Dental (17.0)\
                                                                                                                                                              Abdominal/Thoracic/\
                                                                                                                                                              Orthopedic (13.0)\
                                                                                                                                                              Dermatological (11.0)\
                                                                                                                                                              Unknown (11.0)\
                                                                                                                                                              Electrophysiology (9.0)\
                                                                                                                                                              Ocular (8.0)\
                                                                                                                                                              Other (8.0)\
                                                                                                                                                              Angiography/PCI (6.0)\
                                                                                                                                                              Urologic (4.0)\
                                                                                                                                                              CABG (1.0)

  [22](#rth212076-bib-0022){ref-type="ref"}   Garcia     Yes                                              Apixaban\         2.9% (266)       11.7 (548)\      Dental (14.6)\
                                                                                                          Warfarin                           11.7 (548)       Colonoscopy (9.9)\
                                                                                                                                                              Ocular (8.0)\
                                                                                                                                                              EGD (7.6)\
                                                                                                                                                              PPM (3.5)\
                                                                                                                                                              Cystoscopy (3.2)\
                                                                                                                                                              PCI (2.8)\
                                                                                                                                                              AV Node Ablation (1.0)\
                                                                                                                                                              Pulmonary Vein Isolation (0.8)\
                                                                                                                                                              ICD (0.8)

  [23](#rth212076-bib-0023){ref-type="ref"}   Douketis   No                                               Edoxaban 60\      0% (0)           4.5 (47)\        Angiography/PCI (9.6)\
                                                                                                          Edoxaban 30\                       4.7 (48)\        GI Endoscopy (12.0)\
                                                                                                          Warfarin                           5.2 (55)         Dental (13.6)\
                                                                                                                                                              PPM/ICD (12.7)\
                                                                                                                                                              Ocular (10.8)\
                                                                                                                                                              Orthopedic Surgery (8.0)\
                                                                                                                                                              Genitourinary Surgery (3.9)\
                                                                                                                                                              General Surgery (5.6)\
                                                                                                                                                              Superficial Procedure (7.5)\
                                                                                                                                                              Invasive Diagnostic (11.4)\
                                                                                                                                                              Other (4.9)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AV, Atrioventricular; CABG, Coronary Artery Bypass Grafting; DOAC, Direct Oral Anticoagulant; EGD, Esophagogastroduodenoscopy; PCI, Percutaneous Coronary Intervention; TURP, Transurethral Resection of the Prostate; TURBT, Transurethral Resection of Bladder Tumor; VKA, Vitamin K Antagonist.

John Wiley & Sons, Ltd

###### 

Cohort study procedural characteristics

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References                                  Author     Defined Perioperative Anticoagulation Protocol   DOAC         Emergent (%)   Bridging (%)   Procedural Type (%)
  ------------------------------------------- ---------- ------------------------------------------------ ------------ -------------- -------------- ---------------------------------
  [24](#rth212076-bib-0024){ref-type="ref"}   Schulman   Yes                                              Dabigatran   0              1.7            Endoscopy/Bronchoscopy (21.8)\
                                                                                                                                                     EPS/Ablation (14.6)\
                                                                                                                                                     Cardiac Catheterization (12.4)\
                                                                                                                                                     ICD/PPM (9.6)\
                                                                                                                                                     Joint Surgery (5.4)\
                                                                                                                                                     Abdominal Surgery (5.2)\
                                                                                                                                                     Biopsy (4.4)\
                                                                                                                                                     Ocular (3.9)\
                                                                                                                                                     Vascular (3.5)\
                                                                                                                                                     TURP/TURBT (3.1)\
                                                                                                                                                     Other (16.1)

  [25](#rth212076-bib-0025){ref-type="ref"}   Kosiuk     Yes                                              Dabigatran   0              0              PPM (65.0)\
                                                                                                                                                     ICD (35.0)

  [26](#rth212076-bib-0026){ref-type="ref"}   Terekhov   No                                               Dabigatran   0              0              PPM (100.0)

  [27](#rth212076-bib-0027){ref-type="ref"}   Madan      No                                               Dabigatran   0              0              PPM (55.3)\
                                                                                                                                                     ICD (44.7)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DOAC, Direct Oral Anticoagulant; EPS, Electrophysiology Procedure; ICD, Implantable Cardioverter Defibrillator; PPM, Permanent Pacemaker; TURP, Transurethral Resection of the Prostate; TURBT, Transurethral Resection of Bladder Tumor.

John Wiley & Sons, Ltd

3.3. Postoperative thromboembolic events {#rth212076-sec-0015}
----------------------------------------

Among the eight included studies, there were 38 postoperative thromboembolic events during 9939 DOAC interruptions, yielding a pooled 30‐day postoperative thromboembolic risk of 0.41% (95% CI 0.29‐0.54, *I* ^2^ = 0%) (Tables [4](#rth212076-tbl-0004){ref-type="table"} and [5](#rth212076-tbl-0005){ref-type="table"}). The pooled risk of postoperative thromboembolic events among studies evaluating dabigatran was similar at 0.44% (95% CI 0.26‐ 0.68, *I* ^2^ = 0%) (Table [5](#rth212076-tbl-0005){ref-type="table"}). The meta‐analysis including the 4 randomized controlled trials is reported in Figure [2](#rth212076-fig-0002){ref-type="fig"}A.[20](#rth212076-bib-0020){ref-type="ref"}, [21](#rth212076-bib-0021){ref-type="ref"}, [22](#rth212076-bib-0022){ref-type="ref"}, [23](#rth212076-bib-0023){ref-type="ref"} There were no significant differences between postoperative thromboembolic risk following procedural interruption of DOACs as compared to VKA.

###### 

Postoperative outcomes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References                                  Author     DOAC/Warfarin   30‐Day Thromboembolic (events/Interruptions, %)   30‐Day major bleeding (Events/Interruptions, %)   30‐day Minor Bleeding (events/Interruptions, %)   30‐Day Overall Mortality (events/Interruptions, %)
  ------------------------------------------- ---------- --------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ----------------------------------------------------
  [20](#rth212076-bib-0020){ref-type="ref"}   Healey     Dabigatran\     14/3033 (0.46)\                                   135/3033 (4.45)\                                  259/3033 (8.54)\                                  --
                                                         Warfarin        7/1558 (0.45)                                     72/1558 (4.62)                                    122/1558 (7.83)                                   

  [21](#rth212076-bib-0021){ref-type="ref"}   Sherwood   Rivaroxaban\    4/1297 (0.31)\                                    14/1297 (1.08)\                                   20/1297 (1.54)\                                   1/1297 (0.08)\
                                                         Warfarin        8/1683 (0.48)                                     18/1683 (1.07)                                    24/1683 (1.43)                                    3/1683 (0.18)

  [22](#rth212076-bib-0022){ref-type="ref"}   Garcia     Apixaban\       9/2877 (0.31)\                                    46/2792 (1.65)\                                   26/2792 (0.93)\                                   30/2877 (1.04)\
                                                         Warfarin        10/2864 (0.35)                                    35/2774 (1.26)                                    26/2774 (0.94)                                    15/2864 (0.52)

  [23](#rth212076-bib-0023){ref-type="ref"}   Douketis   Edoxaban\       10/2053 (0.49)\                                   23/2053 (1.12)\                                   56/2053 (2.73)\                                   22/2053 (1.07)\
                                                         Warfarin        6/1063 (0.56)                                     11/1063 (1.03)                                    30/1063 (2.82)                                    13/1063 (1.22)

  [24](#rth212076-bib-0024){ref-type="ref"}   Schulman   Dabigatran      1/531 (0.19)                                      10/531 (1.88)                                     24/531 (4.52)                                     4/531 (0.75)

  [25](#rth212076-bib-0025){ref-type="ref"}   Kosiuk     Dabigatran      0/85 (0)                                          --                                                --                                                0/85 (0)

  [26](#rth212076-bib-0026){ref-type="ref"}   Terekhov   Dabigatran      0/16 (0)                                          0/16 (0)                                          1/16 (6.25)                                       0/16 (0)

  [27](#rth212076-bib-0027){ref-type="ref"}   Madan      Dabigatran      0/47 (0)                                          0/47 (0)                                          0/47 (0)                                          0/47 (0)

  Total                                       --         DOAC\           38/9939 (0.38)\                                   228/9769 (2.33)\                                  386/9769 (3.95)\                                  57/6906 (0.83)\
                                                         Warfarin        31/7168 (0.43)                                    136/7078 (1.92)                                   202/7078 (2.85)                                   31/5610 (0.55)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DOAC, Direct Oral Anticoagulant.

John Wiley & Sons, Ltd

###### 

All DOACs and dabigatran postoperative outcomes pooled incidence analysis

  ** **        30‐day thromboembolic % \[95% CI; *I* ^2^\]   30‐day major bleeding % \[95% CI; *I* ^2^\]   30‐day minor bleeding % \[95% CI; *I* ^2^\]   30‐day overall mortality % \[95% CI\]
  ------------ --------------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------------------------
  Overall      0.41% \[0.29‐0.54; 0%\]                       1.81% \[0.84‐3.1; 92.4%\]                     3.08% \[1.02‐6.20; 97.7%\]                    0.67% \[0.29‐1.23\]
  Dabigatran   0.44% \[0.26‐0.68; 0%\]                       2.56% \[0.92‐4.99; 76.9%\]                    5.15% \[2.21‐9.25; 85.2%\]                    0.74% \[0.24‐1.53\]

DOAC, Direct Oral Anticoagulant.

John Wiley & Sons, Ltd
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3.4. Postoperative major bleeding {#rth212076-sec-0016}
---------------------------------

Seven studies were included in the pooled analysis of major bleeding events. There were a total of 228 major bleeding events during 9769 DOAC interruptions, yielding a pooled 30‐day postoperative major bleeding risk of 1.81% (95% CI 0.8‐3.13, *I* ^2^ = 92.4%) (Table [4](#rth212076-tbl-0004){ref-type="table"} and [5](#rth212076-tbl-0005){ref-type="table"}). The pooled percentage of postoperative major bleeding risk among patients using dabigatran was similar at 2.56% (95% CI 0.92‐4.99, *I* ^*2*^ * *= 76.9%) (Table [5](#rth212076-tbl-0005){ref-type="table"}). The majority of major bleeding events occurred in the perioperative analysis of one randomized trial.[20](#rth212076-bib-0020){ref-type="ref"} The meta‐analysis including the four randomized controlled trials is reported in Figure [2](#rth212076-fig-0002){ref-type="fig"}B.[20](#rth212076-bib-0020){ref-type="ref"}, [21](#rth212076-bib-0021){ref-type="ref"}, [22](#rth212076-bib-0022){ref-type="ref"}, [23](#rth212076-bib-0023){ref-type="ref"} There were no significant differences between postoperative major bleeding episodes following procedural interruption of DOACs as compared to VKA.

3.5. Postoperative minor bleeding {#rth212076-sec-0017}
---------------------------------

Seven of eight studies reporting minor bleeding events were included in the pooled analyses. There were a total of 386 minor bleeding events occurring during 9769 DOAC interruptions, yielding a pooled 30‐day postoperative minor bleeding risk of 3.08% (95% CI 1.02‐6.20, *I* ^2 ^= 97.7%) (Tables [4](#rth212076-tbl-0004){ref-type="table"} and [5](#rth212076-tbl-0005){ref-type="table"}). Similarly, there were no significant differences between postoperative minor bleeding episodes following procedural interruption of DOACs as compared to VKA (Figure [2](#rth212076-fig-0002){ref-type="fig"}C).

3.6. Postoperative all‐cause mortality {#rth212076-sec-0018}
--------------------------------------

Seven out of the eight studies were included in the pooled analysis of 30‐day all‐cause mortality. There were a total of 57 postoperative deaths over 6906 DOAC interruptions, yielding a pooled 30‐day postoperative overall mortality risk of 0.67% (95% CI 0.29‐1.23, *I* ^2^ = 71.3%) (Tables [4](#rth212076-tbl-0004){ref-type="table"} and Table [5](#rth212076-tbl-0005){ref-type="table"}). These results were similar to the pooled all‐cause mortality for dabigatran studies, with a 30‐day overall mortality of 0.74% (95% CI 0.24‐1.53, *I* ^2^ = 0%). There were no significant differences between postoperative overall mortality following procedural interruption of DOACs as compared to VKA (Figure [2](#rth212076-fig-0002){ref-type="fig"}D).

3.7. Quality assessment {#rth212076-sec-0019}
-----------------------

Quality assessment of the randomized trials were carried out using the Cochrane Risk of Bias tool (Supporting information). None of the randomized trials had pre‐defined planned perioperative analyses with defined postoperative outcome definitions (selective reporting). In addition, none of the trials explicitly reported the percentage of patients completing 30‐day following each procedure (incomplete outcome data), although the percentage of patients lost to follow up in the trials was low. The Newcastle‐Ottawa Scale was used to assess the quality of cohort studies (Supporting information). Three out of the 4 included cohort studies did not have adequacy of follow up. In addition, most studies lacked details surrounding derivation of the cohort (eg, sequential recruitment). Three out of four of these studies did not incorporate blinded assessments of the outcomes of interest.

4. DISCUSSION {#rth212076-sec-0020}
=============

The principal finding from our meta‐analysis, which involved over 14,000 patients with AF who had periprocedural VKA or DOAC interruption, is that postoperative adverse outcomes are uncommon following DOAC interruption, with 30‐day postoperative risks of thromboembolism and major bleeding of 0.4% and 1.8%, respectively.

Our pooled results are similar to other large studies evaluating the perioperative interruption of VKA in patients with AF. In a recent randomized controlled trial,[28](#rth212076-bib-0028){ref-type="ref"} the 30‐day postoperative thrombotic risks were 0.4% and 0.3% in the no‐bridging and bridging groups, respectively, which are similar to our pooled DOAC risk of 0.41%. Similarly, the risk of postoperative thromboembolism was 0.4% overall in a recently published prospective registry evaluating the perioperative interruption of VKA.[29](#rth212076-bib-0029){ref-type="ref"} Our pooled major bleeding risk of 1.8% is also comparable to the results of a previously published trial on VKAs, which demonstrated a major bleeding risk of 1.3% and 3.2% in the non‐bridging and bridging groups, respectively. Finally, our reported risk of bleeding events also align with the major bleeding results observed in the ORBIT‐AF registry.[29](#rth212076-bib-0029){ref-type="ref"} Therefore, the results from our meta‐analyses seem to be generalizable to current clinical practices.

The postoperative major and minor bleeding risk seems to be higher in the studies assessing dabigatran for patients with AF. This discrepancy might be accounted for by the higher rates of bridging anticoagulation compared to the other included studies (Table [2](#rth212076-tbl-0002){ref-type="table"}). In addition, the perioperative dabigatran protocol was modified during the conduct of the trials to account for newly available pharmacokinetic data on dabigatran. Initially, dabigatran was held for 24 hours prior to all procedures. The protocol was then amended to hold dabigatran for 24 hours prior low risk surgical procedures and between two to five days prior high risk surgical procedures depending on renal function.[20](#rth212076-bib-0020){ref-type="ref"} This standardized interruption protocol has been shown to yield approximately 85% of patients with no residual anticoagulant effect at the time of procedure and low risk of major bleeding.[30](#rth212076-bib-0030){ref-type="ref"} Therefore, it is possible that dabigatran interruptions that occurred early after initiation of the randomized trials may have contributed to a higher bleeding risk. Furthermore, additional studies on DOAC interruption for elective procedure are needed to confirm these findings.

Our study has potential limitations. First, although several randomized controlled trials are included in our meta‐analysis, it is important to consider that the included data are from post‐hoc analyses of the original clinical trials. None of the randomized trials' protocols described pre‐defined perioperative analyses or postoperative outcome definitions prior to conducting these perioperative analyses.[31](#rth212076-bib-0031){ref-type="ref"}, [32](#rth212076-bib-0032){ref-type="ref"}, [33](#rth212076-bib-0033){ref-type="ref"}, [34](#rth212076-bib-0034){ref-type="ref"} Therefore, the reported pooled estimates might be subject to bias and may underestimate the true 30‐day complications associated with interruption of DOACs. However, these post‐hoc analyses all incorporate widely accepted postoperative outcome definitions based on standard 30‐day complication rates, which would serve to reduce bias. Second, there was significant variability among perioperative anticoagulation practices between the different studies. In particular, only five out of the eight included studies had defined perioperative anticoagulation protocols that clearly instructed physicians on when to stop and re‐start anticoagulation in the event of an invasive procedure (Tables [2](#rth212076-tbl-0002){ref-type="table"} and [3](#rth212076-tbl-0003){ref-type="table"}). Rates of bridging anticoagulation with alternative parenteral anticoagulation also varied significantly between studies. Overall, the rates of bridging were low but varied between 4.5% to 17.0% for DOAC‐treated patients. The timing and dosing of bridging anticoagulation (ie, pre‐operative, peri‐operative or postoperative only) are also unknown.[35](#rth212076-bib-0035){ref-type="ref"} Third, we excluded studies that exclusively evaluated cardiac ablation, as this topic has been extensively studied[36](#rth212076-bib-0036){ref-type="ref"}, [37](#rth212076-bib-0037){ref-type="ref"} This may have biased our results towards lower bleeding rates, as cardiac ablation procedures possibly carry a lower postoperative bleeding risk as compared to major procedures. We also excluded studies that focussed exclusively on emergent procedures. Therefore, our results may not be generalizable to these populations, as emergent procedures likely carry a high bleeding risk. Fourth, we did not have access to patient level data. Therefore, it is possible that we included patients that had more than one DOAC interruption. Finally, we were unable to report results according to procedure types. It is likely that the risk of these clinical outcomes varies depending on the procedure, as there is considerable cross‐procedure variability in risks of bleeding and thromboembolism.[38](#rth212076-bib-0038){ref-type="ref"}

5. CONCLUSIONS {#rth212076-sec-0021}
==============

Interruption of DOACs for invasive procedures is associated with a relatively low risk of postoperative thrombotic and bleeding complications in patients with AF. There is also no significant difference in these risks when compared to the interruption of VKAs. The perioperative interruption of DOACs in patients with AF appears to be safe and effective. These findings are re‐assuring, but require validation in prospective management studies in this patient population.
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